瘤内抗 CTLA-4 治疗：提高疗效，同时避免毒性。
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
机构信息
Authors' Affiliations: Department of Medicine, Division of Oncology, Stanford University, Stanford, California; and Centre de Recherche en Cancérologie de Lyon (CRCL), UMR INSERM U1052 CNRS 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.
出版信息
Clin Cancer Res. 2013 Oct 1;19(19):5261-3. doi: 10.1158/1078-0432.CCR-13-1923. Epub 2013 Aug 21.
Abstract
Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.
摘要
全身性给予检查点阻断抗体抗 CTLA4 会导致严重的自身免疫毒性，限制其临床疗效。Fransen 及其同事在此表明，肿瘤周围给予低剂量的这种免疫调节剂药物可以触发全身性抗肿瘤免疫反应，同时防止对其他器官的毒性。
相似文献
1
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.瘤内抗 CTLA-4 治疗：提高疗效，同时避免毒性。
Clin Cancer Res. 2013 Oct 1;19(19):5261-3. doi: 10.1158/1078-0432.CCR-13-1923. Epub 2013 Aug 21.
2
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.CTLA-4 阻断抗体的局部控制递送诱导 CD8+ T 细胞依赖性肿瘤消除，并降低毒性副作用风险。
Clin Cancer Res. 2013 Oct 1;19(19):5381-9. doi: 10.1158/1078-0432.CCR-12-0781. Epub 2013 Jun 20.
3
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.重新评估 CTLA-4 检查点阻断在癌症免疫治疗中的作用。
Cell Res. 2018 Apr;28(4):416-432. doi: 10.1038/s41422-018-0011-0. Epub 2018 Feb 22.
4
Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.免疫检查点 Ab 通过调节树突状细胞和调节性 T 淋巴细胞增强了抗原特异性抗肿瘤作用。
Cancer Lett. 2019 Mar 1;444:20-34. doi: 10.1016/j.canlet.2018.11.039. Epub 2018 Dec 10.
5
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.瘤内 STING 激活与 T 细胞检查点调节产生全身性抗肿瘤免疫。
Cancer Immunol Res. 2017 Aug;5(8):676-684. doi: 10.1158/2326-6066.CIR-17-0049. Epub 2017 Jul 3.
6
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.肿瘤条件性抗 CTLA4 可将抗肿瘤疗效与免疫治疗相关毒性分离。
J Clin Invest. 2019 Jan 2;129(1):349-363. doi: 10.1172/JCI123391. Epub 2018 Dec 10.
7
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.联合肿瘤冷冻消融与抗 CTLA-4 治疗可强力诱导肿瘤免疫。
Cancer Res. 2012 Jan 15;72(2):430-9. doi: 10.1158/0008-5472.CAN-11-1782. Epub 2011 Nov 22.
8
CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.CTLA-4 和 PD-1 对 T 细胞迁移和运动的控制：对肿瘤免疫治疗的影响。
Front Immunol. 2018 Nov 27;9:2737. doi: 10.3389/fimmu.2018.02737. eCollection 2018.
9
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.给予低剂量联合抗 CTLA4、抗 CD137 和抗 OX40 进入小鼠肿瘤或肿瘤引流淋巴结附近可诱导全身性肿瘤消退。
Cancer Immunol Immunother. 2018 Jan;67(1):47-60. doi: 10.1007/s00262-017-2059-y. Epub 2017 Sep 13.
10
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.PD-1 和 CTLA-4 的双重阻断联合肿瘤疫苗可有效恢复肿瘤中 T 细胞的排斥功能。
Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.
引用本文的文献
1
Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade.肿瘤定位对条件性激活的CTLA-4阻断抗肿瘤免疫的影响。
J Immunother Cancer. 2025 Apr 2;13(4):e010566. doi: 10.1136/jitc-2024-010566.
2
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.对复发性高级别胶质瘤患者进行颅内给予抗程序性死亡受体1（anti-PD-1）和抗细胞毒性T淋巴细胞相关蛋白4（anti-CTLA-4）免疫检查点阻断单克隆抗体治疗。
Neuro Oncol. 2024 Dec 5;26(12):2208-2221. doi: 10.1093/neuonc/noae177.
3
Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.治疗性抗体的替代给药途径——最新技术水平
Antibodies (Basel). 2022 Aug 26;11(3):56. doi: 10.3390/antib11030056.
4
The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8 T lymphocyte/Treg cell balance.IL-2“无α”突变体诱导的抗肿瘤作用依赖于 CD8 T 淋巴细胞/Treg 细胞平衡的改变。
Front Immunol. 2022 Aug 17;13:974188. doi: 10.3389/fimmu.2022.974188. eCollection 2022.
5
Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors.利用抗巨细胞病毒免疫进行局部免疫治疗实体瘤。
Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2116738119. doi: 10.1073/pnas.2116738119. Epub 2022 Jun 24.
6
Intratumoral immunotherapy relies on B and T cell collaboration.肿瘤内免疫治疗依赖于 B 和 T 细胞的协作。
Sci Immunol. 2022 May 27;7(71):eabn5859. doi: 10.1126/sciimmunol.abn5859.
7
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.2021 年 12 月 1 日至 2 日举行的免疫疗法桥 2021 年“大辩论”。
J Transl Med. 2022 Apr 21;20(1):179. doi: 10.1186/s12967-022-03384-w.
8
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8 T cell immunity to reject 'cold' tumors.基于载体的 Treg 耗竭型 αCTLA-4 引发抗原交叉呈递和 CD8 T 细胞免疫，以排斥“冷”肿瘤。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003488.
9
Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination.咪喹莫特联合 OX40 激动剂原位疫苗接种清除肿瘤。
Cancer Sci. 2021 Nov;112(11):4490-4500. doi: 10.1111/cas.15145. Epub 2021 Sep 27.
10
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.脑内给予 CTLA-4 和 PD-1 免疫检查点阻断单克隆抗体治疗复发性胶质母细胞瘤患者的 I 期临床试验
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002296.
本文引用的文献
1
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.IgG2a 同种型的抗 CTLA-4 抗体通过减少肿瘤内调节性 T 细胞增强抗肿瘤活性。
Cancer Immunol Res. 2013 Jul;1(1):32-42. doi: 10.1158/2326-6066.CIR-13-0013. Epub 2013 Apr 7.
2
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.CTLA-4 阻断抗体的局部控制递送诱导 CD8+ T 细胞依赖性肿瘤消除，并降低毒性副作用风险。
Clin Cancer Res. 2013 Oct 1;19(19):5381-9. doi: 10.1158/1078-0432.CCR-12-0781. Epub 2013 Jun 20.
3
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.在单一部位耗尽肿瘤特异性 Tregs 可消除播散性肿瘤。
J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859.
4
Nivolumab plus ipilimumab in advanced melanoma.纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
5
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
6
Cancer immunotherapy comes of age.癌症免疫疗法崭露头角。
Nature. 2011 Dec 21;480(7378):480-9. doi: 10.1038/nature10673.
7
Cancer immunotherapy comes of age.癌症免疫疗法走向成熟。
J Clin Oncol. 2011 Dec 20;29(36):4828-36. doi: 10.1200/JCO.2011.38.0899. Epub 2011 Oct 31.
8
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.改变癌症免疫编辑的平衡点：从肿瘤耐受到消除。
Immunol Rev. 2011 May;241(1):104-18. doi: 10.1111/j.1600-065X.2011.01007.x.
9
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
10
CTLA-4 control over Foxp3+ regulatory T cell function.细胞毒性T淋巴细胞相关抗原4对叉头框蛋白3阳性调节性T细胞功能的调控
Science. 2008 Oct 10;322(5899):271-5. doi: 10.1126/science.1160062.
Zotero 插件